Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ·Healthcare·Biotechnology
$6.56
-3.88%
Mkt Cap $53.91M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 11, 2026 | $4.52M | $5.09M | +12.65% | -$0.43 | -$0.56 | -30.23% | — | — |
| Q4 2025 Nov 14, 2025 | $4.52M | $14.34M | +217.35% | -$1.14 | $0.13 | +111.40% | — | — |
| Q3 2025 Aug 12, 2025 | $6.45M | $12.70M | +96.93% | -$0.70 | $0.02 | +102.86% | — | — |
| Q2 2025 May 13, 2025 | $3.53M | $3.44M | -2.65% | -$1.40 | -$1.00 | +28.57% | — | — |
| Q1 2025 Mar 11, 2025 | $2.11M | $344.00K | -83.69% | -$0.25 | -$0.24 | +4.00% | — | — |
| Q4 2024 Nov 4, 2024 | $530.00K | -$1.78M | -436.04% | -$0.37 | -$0.49 | -32.43% | — | — |
| Q3 2024 Aug 14, 2024 | $4.37M | $5.18M | +18.47% | -$0.43 | -$0.31 | +27.91% | — | — |
| Q2 2024 May 13, 2024 | $2.78M | $3.83M | +37.63% | -$0.54 | -$0.38 | +29.63% | — | — |
| Q1 2024 Feb 29, 2024 | $910.00K | $1.99M | +118.46% | -$0.47 | -$0.48 | -2.13% | — | — |
| Q4 2023 Nov 9, 2023 | $510.00K | $2.92M | +471.96% | -$0.22 | -$0.32 | -45.45% | — | — |
| Q3 2023 Aug 8, 2023 | $70.00K | $182.00K | +160.00% | -$0.22 | -$0.21 | +4.55% | — | — |
| Q2 2023 May 9, 2023 | $430.00K | $37.00K | -91.40% | -$0.20 | -$0.13 | +35.00% | — | — |
| Q1 2023 Mar 6, 2023 | $312.50K | $68.00K | -78.24% | -$0.20 | -$0.11 | +45.00% | — | — |
| Q4 2022 Nov 7, 2022 | $4.33M | $8.32M | +92.14% | -$0.11 | $0.07 | +163.64% | — | — |
| Q3 2022 Aug 11, 2022 | $312.50K | $214.00K | -31.52% | -$0.32 | -$0.32 | +0.00% | — | — |
| Q2 2022 May 9, 2022 | $332.40K | $431.00K | +29.66% | -$0.54 | -$0.25 | +53.70% | — | — |
| Q1 2022 Mar 2, 2022 | $260.00K | -$12.00M | -4715.38% | -$0.48 | -$0.35 | +27.08% | — | — |
| Q4 2021 Nov 12, 2021 | — | — | — | -$0.49 | -$0.40 | +18.37% | — | — |
| Q3 2021 Aug 10, 2021 | $250.00K | — | — | -$0.41 | -$0.35 | +14.63% | — | — |
| Q2 2021 May 7, 2021 | $20.37M | $12.00M | -41.08% | -$0.35 | $0.02 | +105.71% | — | — |